Trial Profile
Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents - A Phase II Study HIT-HGG-CilMetro - A Clinical Phase II Trial of the HIT-HGG Study Group.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs Cilengitide (Primary) ; Temozolomide (Primary)
- Indications Anaplastic astrocytoma; Diffuse intrinsic pontine glioma; Glioblastoma; Glioma; Gliosarcoma; Oligodendroglioma
- Focus Therapeutic Use
- Acronyms HGG-Cil-Metro; HIT-HGG-CilMetro
- 05 Oct 2021 Status changed from discontinued to completed.
- 13 Jun 2014 European Clinical Trials Database record mentions trial status as ongoing.
- 24 Apr 2014 Status changed from recruiting to discontinued, as per ClinicalTrials.gov record.